Literature DB >> 16873674

Overexpression of CEBPA resulting from the translocation t(14;19)(q32;q13) of human precursor B acute lymphoblastic leukemia.

Elise Chapiro1, Lisa Russell, Isabelle Radford-Weiss, Christian Bastard, Michel Lessard, Stephanie Struski, Helene Cave, Sandra Fert-Ferrer, Carole Barin, Odile Maarek, Veronique Della-Valle, Jonathan C Strefford, Roland Berger, Christine J Harrison, Olivier A Bernard, Florence Nguyen-Khac.   

Abstract

Subtle variation in the expression or function of a small group of transcription factors can drive leukemogenesis. The CEBPA protein is known to regulate the balance between cell proliferation and differentiation during early hematopoietic development and myeloid differentiation. In human myeloid leukemia, CEBPA is frequently inactivated by mutation and indirect and posttranslational mechanisms, in keeping with tumor suppressor properties. We report that CEBPA is activated by juxtaposition to the immunoglobulin gene enhancer upon its rearrangement with the immunoglobulin heavy-chain locus in precursor B-cell acute lymphoblastic leukemia harboring t(14;19)(q32;q13). Overexpression of apparently normal CEBPA RNA or protein was observed in 6 patients. These data indicate that CEBPA may exhibit oncogenic as well as tumor suppressor properties in human leukemogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16873674     DOI: 10.1182/blood-2006-03-010835

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  21 in total

1.  Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1.

Authors:  Bas J Wouters; Meritxell Alberich Jordà; Karen Keeshan; Irene Louwers; Claudia A J Erpelinck-Verschueren; Dennis Tielemans; Anton W Langerak; Yiping He; Yumi Yashiro-Ohtani; Pu Zhang; Christopher J Hetherington; Roel G W Verhaak; Peter J M Valk; Bob Löwenberg; Daniel G Tenen; Warren S Pear; Ruud Delwel
Journal:  Blood       Date:  2007-08-01       Impact factor: 22.113

2.  IGH@ translocations co-exist with other primary rearrangements in B-cell precursor acute lymphoblastic leukemia.

Authors:  Sally J Jeffries; Lisa Jones; Christine J Harrison; Lisa J Russell
Journal:  Haematologica       Date:  2014-05-09       Impact factor: 9.941

3.  A novel IGH@ gene rearrangement associated with CDKN2A/B deletion in young adult B-cell acute lymphoblastic leukemia.

Authors:  Moneeb A K Othman; Beata Grygalewicz; Barbara Pienkowska-Grela; Jolanta Rygier; Anna Ejduk; Martina Rincic; Joana B Melo; Isabel M Carreira; Britta Meyer; Thomas Liehr
Journal:  Oncol Lett       Date:  2016-01-29       Impact factor: 2.967

4.  Allogeneic Hematopoietic Stem Cell Transplantation with Myeloablative Conditioning Is Associated with Favorable Outcomes in Mixed Phenotype Acute Leukemia.

Authors:  Bartlomiej M Getta; Mikhail Roshal; Junting Zheng; Jae H Park; Eytan M Stein; Ross Levine; Esperanza B Papadopoulos; Ann A Jakubowski; Nancy A Kernan; Peter Steinherz; Richard J O'Reilly; Miguel-Angel Perales; Sergio A Giralt; Martin S Tallman; Brian C Shaffer
Journal:  Biol Blood Marrow Transplant       Date:  2017-07-08       Impact factor: 5.742

Review 5.  C/EBPα dysregulation in AML and ALL.

Authors:  Ido Paz-Priel; Alan Friedman
Journal:  Crit Rev Oncog       Date:  2011

Review 6.  Dysregulation of the C/EBPalpha differentiation pathway in human cancer.

Authors:  Steffen Koschmieder; Balazs Halmos; Elena Levantini; Daniel G Tenen
Journal:  J Clin Oncol       Date:  2008-12-15       Impact factor: 44.544

7.  Malignant transformation initiated by Mll-AF9: gene dosage and critical target cells.

Authors:  Weili Chen; Ashish R Kumar; Wendy A Hudson; Quanzhi Li; Baolin Wu; Rodney A Staggs; Erik A Lund; Thien N Sam; John H Kersey
Journal:  Cancer Cell       Date:  2008-05       Impact factor: 31.743

8.  A rare case of acute lymphoblastic leukemia in a patient with light chain (AL) amyloidosis treated with lenalidomide.

Authors:  Ranjit Nair; Shereen Gheith; Dan Popescu; Nicole M Agostino
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

Review 9.  Sumoylation and the function of CCAAT enhancer binding protein alpha (C/EBP alpha).

Authors:  Arati Khanna-Gupta
Journal:  Blood Cells Mol Dis       Date:  2008-04-10       Impact factor: 3.039

10.  Maximal STAT5-induced proliferation and self-renewal at intermediate STAT5 activity levels.

Authors:  Albertus T J Wierenga; Edo Vellenga; Jan Jacob Schuringa
Journal:  Mol Cell Biol       Date:  2008-09-08       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.